Government worse than the market in distributing monoclonal antibodies

 Epoch Times:

The head of a medical supplies company involved in the distribution and supply of monoclonal antibodies across southeastern and northeastern regions of the nation, told NTD in a Jan. 12 interview that government takeover of the monoclonal antibody supply chain has exacerbated backlogs and shortages.

“The way the products are being distributed right now, relying on the government to determine who gets what, that process can be very lengthy in terms of time,” Dealmed CEO Michael Einhorn said.

As a result, physicians are reporting “surpluses in certain areas, not enough in other areas” which has fueled frustrations when critical patients are not receiving antibodies for COVID-19 infections.

While it’s unclear how the monoclonal antibodies are being rationed among states, Einhorn said that “commercialization” of these products should be allowed, so that infusion centers that need them can order in products based on “patient volume.”

“If they have oversupply they wouldn’t order more,” Einhorn said, whereas when remedies are supplied by the state, “nobody’s going to say no the government” as the products are “free practically,” leading to mismatches in supply and demand.
...

I blame Biden and Democrats who were trying to block Florida and Texas from using the therapeutics.  The supply problem happened as soon as Biden had the government take over the distribution.

Comments

Popular posts from this blog

Should Republicans go ahead and add Supreme Court Justices to head off Democrats

29 % of companies say they are unlikely to keep insurance after Obamacare

Bin Laden's concern about Zarqawi's remains